Negara: Amerika Serikat
Bahasa: Inggris
Sumber: NLM (National Library of Medicine)
MORPHINE SULFATE (UNII: X3P646A2J0) (MORPHINE - UNII:76I7G6D29C)
Lake Erie Medical DBA Quality Care Products LLC
MORPHINE SULFATE
MORPHINE SULFATE 20 mg
PRESCRIPTION DRUG
New Drug Application
KADIAN- MORPHINE SULFATE CAPSULE, EXTENDED RELEASE
LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
KADIAN (MORPHINE SULFATE) EXTENDED-RELEASE CAPSULES, FOR ORAL USE, CII
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
KADIAN SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR KADIAN.
KADIAN® (MORPHINE SULFATE) EXTENDED-RELEASE CAPSULES, FOR ORAL USE,
CII
INITIAL U.S. APPROVAL: 1941
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY
DEPRESSION;
ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND
INTERACTION
WITH ALCOHOL
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
KADIAN EXPOSES USERS TO RISKS OF ADDICTION, ABUSE, AND MISUSE, WHICH
CAN LEAD TO OVERDOSE AND DEATH.
ASSESS EACH PATIENT’S RISK BEFORE PRESCRIBING, AND MONITOR REGULARLY
FOR DEVELOPMENT OF THESE
BEHAVIORS OR CONDITIONS. (5.1)
SERIOUS, LIFE-THREATENING, OR FATAL RESPIRATORY DEPRESSION MAY OCCUR.
MONITOR CLOSELY, ESPECIALLY UPON
INITIATION OR FOLLOWING A DOSE INCREASE. INSTRUCT PATIENTS TO SWALLOW
KADIAN CAPSULES WHOLE TO AVOID
EXPOSURE TO A POTENTIALLY FATAL DOSE OF MORPHINE. (5.2)
ACCIDENTAL INGESTION OF KADIAN, ESPECIALLY IN CHILDREN, CAN RESULT IN
FATAL OVERDOSE OF MORPHINE. (5.3)
PROLONGED USE OF KADIAN DURING PREGNANCY CAN RESULT IN NEONATAL OPIOID
WITHDRAWAL SYNDROME, WHICH
MAY BE LIFE-THREATENING IF NOT RECOGNIZED AND TREATED. IF OPIOID USE
IS REQUIRED FOR A PROLONGED PERIOD
IN A PREGNANT WOMAN, ADVISE THE PATIENT OF THE RISK OF NEONATAL OPIOID
WITHDRAWAL SYNDROME AND
ENSURE THAT APPROPRIATE TREATMENT WILL BE AVAILABLE. (5.3)
INSTRUCT PATIENTS NOT TO CONSUME ALCOHOL OR ANY PRODUCTS CONTAINING
ALCOHOL WHILE TAKING KADIAN
BECAUSE CO-INGESTION CAN RESULT IN FATAL PLASMA MORPHINE LEVELS. (5.4)
RECENT MAJOR CHANGES
Boxed Warning
04/2014
Indications and Usage (1)
04/2014
Dosage and Administration (2) 04/2014
Warnings and Precautions (5)
04/2014
Baca dokumen lengkapnya
Peringatan pencarian terkait dengan produk ini
Lihat riwayat dokumen